Immutep

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immutep and other ETFs, options, and stocks.

About IMMP

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). 

CEO
Marc Voigt
CEOMarc Voigt
Employees
Employees
Headquarters
Sydney, New South Wales (NSW)
HeadquartersSydney, New South Wales (NSW)
Founded
1987
Founded1987
Employees
Employees

IMMP Key Statistics

Market cap
55.43M
Market cap55.43M
Price-Earnings ratio
-1.01
Price-Earnings ratio-1.01
Dividend yield
Dividend yield
Average volume
393.84K
Average volume393.84K
High today
$0.39
High today$0.39
Low today
$0.3702
Low today$0.3702
Open price
$0.3702
Open price$0.3702
Volume
236.44K
Volume236.44K
52 Week high
$3.53
52 Week high$3.53
52 Week low
$0.2928
52 Week low$0.2928

IMMP News

Simply Wall St 14h
Here's Why We're Watching Immutep's Cash Burn Situation - simplywall.st

...

Here's Why We're Watching Immutep's Cash Burn Situation - simplywall.st
TipRanks 3d
Immutep upgraded to Buy from Hold at Maxim

Maxim analyst Jason McCarthy upgraded Immutep (IMMP) to Buy from Hold with a $1.50 price target Published first on TheFly – the ultimate source for real-time,...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.